Validity of claims data for identifying cancer incidence in the Japan public health center-based prospective study for the next generation
Validity of claims data for identifying cancer incidence in the Japan public health center-based prospective study for the next generation
复制标题
DOI：
10.1002/pds.5494
复制
发表时间：
2022-06-25
影响因子：
2.6
通讯作者：
Tsugane，Shoichiro
中科院分区：
文献类型：
--
作者：
Ihira，Hikaru;Goto，Atsushi;Tsugane，Shoichiro
PurposeThis study determined the validity of claims‐based definitions for identifying the incidence of total and site‐specific cancers in a population based cohort study.MethodsClaims数据来自21 946名年龄在40-74岁的参与者，这些参与者参加了日本公共卫生中心的下一代前瞻性研究。我们使用索赔数据中的代码组合（包括癌症治疗的诊断和程序代码）定义了总癌症发病率和研究中心特定癌症发病率。从癌症登记处的数据被用作金标准，以评估validity.ResultsAmong 21 946名参与者，454总，89胃，67结直肠癌，51肺，39乳腺癌和99前列腺浸润癌病例中新诊断的癌症登记处。对于浸润性癌，联合诊断代码和治疗程序定义的敏感性和特异性分别为87.0%和99.4%，胃癌88.8%和99.9%，结直肠80.6%和99.9%，肺癌86.3%和99.9%，乳腺癌为100%和99.9%，前列腺癌为91.9%和99.9%。此外，对于浸润性和/或原位癌，该定义的敏感性和特异性分别为84.5%和99.5%（总），66.7%和99.9%（结直肠癌），100%和99.9%（乳腺癌）。乳腺癌和前列腺癌的发病率，但可能低估了结直肠癌的发病率。
PurposeThis study determined the validity of claims‐based definitions for identifying the incidence of total and site‐specific cancers in a population‐based cohort study.MethodsClaims data were obtained for 21 946 participants aged 40–74 years enrolled in the Japan Public Health Center‐based Prospective Study for the Next Generation. We defined total and site‐specific cancer incidence using combinations of codes from claims data, including diagnosis and procedure codes for cancer therapy. Data from the cancer registry were used as the gold standard to evaluate validity.ResultsAmong 21 946 participants, 454 total, 89 stomach, 67 colorectal, 51 lung, 39 breast and 99 prostate invasive cancer cases were newly diagnosed in the cancer registry. For invasive cancer, the sensitivity and specificity of the definition that combined codes for diagnosis and procedures for cancer therapy were 87.0% and 99.4% for total, 88.8% and 99.9% for stomach, 80.6% and 99.9% for colorectal, 86.3% and 99.9% for lung, 100% and 99.9% for breast and 91.9% and 99.9% for prostate cancer, respectively. Furthermore, for invasive and/or in situ cancer, the sensitivity and specificity of the definition were 84.5% and 99.5% for total, 66.7% and 99.9% for colorectal and 100% and 99.9% for breast cancer.ConclusionsOur findings suggest that claims‐based definitions using diagnosis and procedure codes generally have high validity for total, stomach, lung, breast and prostate cancer incidence, but may underestimate colorectal cancer incidence.